Breaking News
InnovAge Announces Release of CMS Sanction in Sacramento Center
InnovAge, a market-leading healthcare delivery platform for high-cost, dual-eligible seniors, announced today that the Centers for Medicare & Medicaid Services (CMS) has determined that effective immediately the sanction is released from InnovAge in Sacramento, California and it will return to normal enrollment status for Medicare-eligible participants.
The California Department of Health Care Services (DHCS) continues to conduct its validation audit and has not lifted the state sanction. The DHCS audit outcome determines InnovAge’s ability to enroll Medicaid recipients, which is required to enroll seniors with both Medicare and Medicaid.
“Today’s announcement is a step in the right direction, and we are proud of our team for the work they have done to address the audit findings and strengthen our end-to-end operations,” said InnovAge President and Chief Executive Officer Patrick Blair. “We recognize there is still work to do, and we look forward to working with both CMS and our state partners to ensure we are providing the highest quality care and access to all Sacramento-area eligible seniors.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program
Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program
Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, […]